ABCL Cumulative FCF
The running total of free cash flow across the series, showing cumulative cash generated to date.
Cumulative FCF
Latest: −$495M (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | −$59M |
| 2023Q2 | −$66M |
| 2023Q3 | −$87M |
| 2023Q4 | −$121M |
| 2024Q1 | −$187M |
| 2024Q2 | −$237M |
| 2024Q3 | −$284M |
| 2024Q4 | −$308M |
| 2025Q1 | −$330M |
| 2025Q2 | −$376M |
| 2025Q3 | −$437M |
| 2025Q4 | −$482M |
| 2026Q1 | −$519M |
| 2026Q2 | −$495M |
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 8
Revenue
EPS
Free Cash Flow
FCF Margin
P/E Ratio
Shares Outstanding
Total Assets
Rule of 40
Healthcare Comparison
1 / 3
Cumulative FCF
Cumulative FCF
Cumulative FCF
Latest Cumulative FCF: −$495M (2026Q2); −31.8% YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, Cumulative FCF ranged from −$519M in 2026Q1 to −$59M in 2023Q1.